Suppliers and packagers for ARIPIPRAZOLE

ARIPIPRAZOLE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Amneal Pharms	ARIPIPRAZOLE	aripiprazole	SOLUTION;ORAL	203906	ANDA	Amneal Pharmaceuticals LLC	65162-893-74	1 BOTTLE in 1 CARTON (65162-893-74) / 150 mL in 1 BOTTLE	2015-08-17
Apotex	ARIPIPRAZOLE	aripiprazole	SOLUTION;ORAL	204094	ANDA	Apotex Corp.	60505-0404-5	1 BOTTLE in 1 CARTON (60505-0404-5) / 150 mL in 1 BOTTLE	2015-10-08
Aurobindo Pharma Ltd	ARIPIPRAZOLE	aripiprazole	SOLUTION;ORAL	210479	ANDA	Aurobindo Pharma Limited	59651-110-55	1 BOTTLE in 1 CARTON (59651-110-55) / 150 mL in 1 BOTTLE	2019-01-29
Chartwell Rx	ARIPIPRAZOLE	aripiprazole	SOLUTION;ORAL	215595	ANDA	Chartwell RX, LLC	62135-904-51	150 mL in 1 BOTTLE (62135-904-51)	2022-10-25

ARIPIPRAZOLE API SUPPLIERS: GLOBAL SUPPLY CHAIN ANALYSIS

Last updated: February 19, 2026

This report identifies and analyzes key suppliers of aripiprazole active pharmaceutical ingredient (API). The global market for aripiprazole API is characterized by a concentration of manufacturers in Asia, primarily China and India, with several European and North American companies also operating. Key considerations for procurement include manufacturing capacity, regulatory compliance, quality control, and pricing.

WHAT IS ARIPI জলে?

Aripiprazole is an atypical antipsychotic medication used to treat schizophrenia, bipolar disorder, major depressive disorder, and irritability associated with autistic disorder. It functions as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and an antagonist at serotonin 5-HT2A receptors. The development of aripiprazole by Otsuka Pharmaceutical resulted in significant patent protection, which has since expired in major markets, leading to increased generic competition and demand for API suppliers.

KEY GLOBAL ARIPIPIZOLE API SUPPLIERS

The supply of aripiprazole API is dominated by manufacturers in China and India due to cost advantages and established chemical manufacturing infrastructure. Several established pharmaceutical ingredient manufacturers globally produce aripiprazole API, catering to both generic and branded drug manufacturers.

Major Manufacturing Hubs

• China: Accounts for a significant portion of global API production, including aripiprazole, owing to lower manufacturing costs and extensive chemical synthesis capabilities. Companies in China often possess large-scale production facilities and export worldwide.
• India: Another dominant player in the API market. Indian manufacturers are known for their expertise in complex chemical synthesis and adherence to international regulatory standards. Many have strong R&D capabilities for process optimization.
• Europe: Several European countries, including Germany and Switzerland, have manufacturers that produce high-quality aripiprazole API, often focusing on niche markets or specialized formulations. These suppliers typically command premium pricing.
• North America: While less dominant in sheer volume compared to Asia, North American suppliers provide aripiprazole API, often with a strong emphasis on regulatory compliance and domestic supply chain security.

Identified Key Suppliers and Their Capabilities

The following companies are recognized for their substantial involvement in the production and supply of aripiprazole API. This list is not exhaustive but represents prominent players based on market presence, production capacity, and regulatory filings.

Supplier Company	Country of Origin	Primary Focus	Key Certifications (Examples)	Notes
Nanjing Chemical Pharmaceutical Co., Ltd.	China	Large-scale API manufacturing	ISO 9001, GMP (various authorities)	Known for high-volume production and competitive pricing. Supplies to multiple global markets.
Hubei Biocause Pharmaceutical Co., Ltd.	China	Broad range of APIs, including antipsychotics	FDA inspected, CEP (Certificate of Suitability)	Significant production capacity for aripiprazole. Often cited in generic drug filings.
Divi's Laboratories Ltd.	India	Custom synthesis, generic APIs	US FDA, EDQM, PMDA (Japan)	One of India's largest API manufacturers. Known for robust quality control and regulatory dossier support.
Laurus Labs Limited	India	APIs for various therapeutic areas, including CNS drugs	US FDA, EDQM, WHO-GMP	Strong focus on R&D and process innovation. Has significant capacity for aripiprazole and its intermediates.
Dr. Reddy's Laboratories	India	Generic APIs and finished dosage forms	US FDA, EMA, WHO-GMP	Established global presence. Offers aripiprazole API with comprehensive regulatory support.
Aurobindo Pharma	India	Vertically integrated pharmaceutical company, API division	US FDA, EMA, ANVISA (Brazil)	Significant producer of generic APIs. Aripiprazole is part of their CNS API portfolio.
Sun Pharmaceutical Industries Ltd.	India	Largest Indian pharma company, extensive API portfolio	US FDA, EMA, TGA (Australia)	A major global player with substantial API manufacturing capabilities, including aripiprazole.
Teva Pharmaceutical Industries Ltd.	Israel	World's largest generic drug manufacturer, API division	US FDA, EMA	While primarily known for finished dosages, Teva's API division is a significant producer of various APIs, including aripiprazole.
Bristol-Myers Squibb (API Manufacturing Sites)	USA / Global	Branded pharmaceutical manufacturing	US FDA, EMA	Historically a primary producer of branded aripiprazole (Abilify). May supply API for specific formulations or legacy products.
Hikma Pharmaceuticals	UK / Global	Generic injectables and APIs	US FDA, EMA	Known for its global reach and focus on complex generics. Produces aripiprazole API.

Regulatory Landscape and Compliance

Manufacturers seeking to supply aripiprazole API to regulated markets must adhere to stringent quality and regulatory standards. Key authorities and their requirements include:

• U.S. Food and Drug Administration (FDA): Requires adherence to Current Good Manufacturing Practices (cGMP). Facilities are subject to inspection. Drug Master Files (DMFs) are typically submitted.
• European Medicines Agency (EMA): Requires compliance with EU GMP guidelines and the submission of a Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP) for APIs.
• Other National Regulatory Bodies: Agencies in Japan (PMDA), Canada (Health Canada), Australia (TGA), and others have their own specific requirements for API registration and quality control.

MANUFACTURING PROCESS AND QUALITY CONTROL

The synthesis of aripiprazole involves multi-step chemical reactions. Key intermediates and process controls are critical for ensuring the purity, efficacy, and safety of the final API.

Key Synthesis Routes

While specific proprietary synthesis routes vary among manufacturers, common approaches involve the coupling of key chemical moieties. For example, a common strategy involves the reaction of a piperazine derivative with a quinolinone derivative. The efficiency and cost-effectiveness of these routes, along with the ability to control impurities, are critical competitive factors.

Impurity Profiling and Control

The identification and control of process-related impurities and degradation products are paramount for API manufacturers. Regulatory authorities require comprehensive impurity profiles. Specific impurities that may arise during aripiprazole synthesis include:

• Starting Material Residues: Unreacted precursors.
• By-products: Compounds formed through unintended side reactions.
• Degradation Products: Resulting from instability under storage or processing conditions.

Manufacturers must establish robust analytical methods (e.g., High-Performance Liquid Chromatography - HPLC, Gas Chromatography - GC, Mass Spectrometry - MS) to detect and quantify these impurities. Limits for impurities are set based on pharmacopoeial standards and toxicological assessments.

Quality Management Systems

Aripiprazole API suppliers must operate under a comprehensive Quality Management System (QMS). This includes:

• Batch Record Keeping: Detailed documentation of every production batch.
• Change Control Procedures: Management of any modifications to processes, equipment, or materials.
• Deviation Management: Investigation and resolution of any deviations from standard operating procedures.
• Supplier Qualification: Rigorous assessment of raw material and intermediate suppliers.
• Validation: Process validation, analytical method validation, and equipment qualification.

MARKET DYNAMICS AND PRICING

The aripiprazole API market is influenced by several factors:

Genericization and Competition

The expiry of primary patents for aripiprazole (e.g., Abilify® by Otsuka Pharmaceutical) has led to increased generic competition. This has driven down the prices of finished dosage forms and, consequently, increased the demand for cost-effective API from generic manufacturers. The number of approved generic aripiprazole products in major markets directly correlates with API demand.

Supply Chain Resilience and Risk Mitigation

Recent global events have highlighted the importance of supply chain resilience. Pharmaceutical companies sourcing aripiprazole API are increasingly looking for suppliers with:

• Multiple Manufacturing Sites: To mitigate risks of regional disruptions.
• Strong Business Continuity Plans: For unforeseen events (e.g., natural disasters, geopolitical instability).
• Geographic Diversification: Reducing reliance on single countries or regions.

Pricing Factors

The price of aripiprazole API is influenced by:

• Manufacturing Costs: Raw materials, labor, energy, and capital investment.
• Scale of Production: Larger batches generally result in lower per-unit costs.
• Regulatory Compliance Costs: Investments in quality systems and dossier preparation.
• Market Demand: High demand can support higher prices, while oversupply can lead to price erosion.
• Geographic Origin: Asian manufacturers typically offer more competitive pricing compared to European or North American suppliers.
• Purity and Specifications: Meeting stringent pharmacopoeial or customer-specific requirements can impact cost.

FUTURE TRENDS AND CONSIDERATIONS

The aripiprazole API market is expected to continue to be robust, driven by the ongoing need for antipsychotic and antidepressant treatments.

Process Innovation and Green Chemistry

Manufacturers will likely focus on optimizing synthesis routes to improve yields, reduce waste, and lower production costs. The adoption of green chemistry principles to minimize environmental impact will also become more prevalent.

Emerging Markets

Growth in demand for aripiprazole is anticipated in emerging economies as healthcare access and awareness of mental health conditions increase. This will create opportunities for API suppliers to expand their reach.

Specialized Formulations

While the bulk API market is significant, there may be niche opportunities for suppliers capable of producing aripiprazole API for specialized formulations, such as long-acting injectables or specific polymorphs with desired pharmacokinetic properties.

KEY TAKEAWAYS

• The global aripiprazole API supply chain is concentrated in China and India, driven by cost efficiencies and established manufacturing capabilities.
• Key global suppliers include Nanjing Chemical Pharmaceutical, Hubei Biocause, Divi's Laboratories, Laurus Labs, Dr. Reddy's Laboratories, Aurobindo Pharma, and Sun Pharmaceutical.
• Regulatory compliance with authorities like the FDA and EMA is critical for market access. Manufacturers must maintain robust Quality Management Systems and comprehensive impurity profiling.
• The market is characterized by strong generic competition, which places pressure on API pricing and emphasizes cost-effective manufacturing.
• Supply chain resilience, geographic diversification, and process innovation will be increasingly important factors for pharmaceutical companies in their API sourcing strategies.

FAQS

What are the primary regulatory requirements for aripiprazole API suppliers exporting to the United States?

Suppliers must comply with U.S. FDA Current Good Manufacturing Practices (cGMP). This includes adherence to quality systems, facility standards, and manufacturing process controls. Submission of a Drug Master File (DMF) detailing the API's manufacturing, controls, and specifications is typically required to support new drug applications (NDAs) and abbreviated new drug applications (ANDAs) filed by finished drug product manufacturers.

How does the patent status of aripiprazole affect API suppliers?

The expiration of primary patents for aripiprazole has opened the market to generic manufacturers. This significantly increases the demand for aripiprazole API from these generic companies, driving competition among API suppliers to provide high-quality, cost-effective products. It also allows for greater flexibility in who can manufacture and supply the API.

What are the typical quality control measures for aripiprazole API?

Quality control measures include rigorous testing of raw materials, in-process controls at various stages of synthesis, and comprehensive final API testing. This testing typically involves assays for potency, identification tests, limits for related substances (impurities), residual solvents, heavy metals, and physical characteristics (e.g., particle size distribution). Analytical methods such as HPLC, GC, and spectroscopy are routinely employed.

How can a pharmaceutical company assess the reliability of an aripiprazole API supplier?

Reliability assessment involves a multi-faceted approach. This includes reviewing the supplier's regulatory history (e.g., FDA inspection outcomes), verifying their GMP certifications and any Certificates of Suitability (CEP), evaluating their quality management system, assessing their manufacturing capacity and ability to scale, understanding their supply chain transparency, and potentially conducting site audits. References from other customers can also be valuable.

What is the impact of geopolitical instability on the aripiprazole API supply chain?

Geopolitical instability can lead to disruptions in raw material sourcing, manufacturing operations, and transportation logistics, impacting the availability and cost of aripiprazole API. It can also influence trade policies and tariffs. Companies are increasingly mitigating these risks by diversifying their supplier base across different geographic regions and securing longer-term contracts.

CITATIONS

[1] U.S. Food and Drug Administration. (n.d.). Guidance for Industry. Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidance-industry

[2] European Medicines Agency. (n.d.). Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP). Retrieved from https://www.ema.europa.eu/en/human-regulatory/production-quality-scientific-evaluation/certificate-suitability-monographs-european-pharmacopoeia

[3] Otsuka Pharmaceutical Co., Ltd. (n.d.). Company History. Retrieved from Otsuka's official website (specific URL may vary).

[4] Divi's Laboratories Ltd. (n.d.). Product Portfolio. Retrieved from Divi's Laboratories official website.

[5] Laurus Labs Limited. (n.d.). APIs. Retrieved from Laurus Labs official website.

[6] Dr. Reddy's Laboratories. (n.d.). APIs. Retrieved from Dr. Reddy's Laboratories official website.

[7] Sun Pharmaceutical Industries Ltd. (n.d.). API Division. Retrieved from Sun Pharmaceutical Industries official website.

[8] Teva Pharmaceutical Industries Ltd. (n.d.). API Business. Retrieved from Teva Pharmaceutical Industries official website.